Insulin Glargine vs Insulin Degludec
Insulin glargine and insulin degludec represent two distinct engineering strategies for achieving prolonged basal insulin coverage. Glargine achieves a relatively flat 24-hour profile through pH-dependent precipitation at subcutaneous injection sites, while degludec forms soluble multi-hexamer chains that slowly dissociate and bind albumin, producing an ultra-long half-life exceeding 42 hours.
Structural and Mechanistic Differences
Section titled “Structural and Mechanistic Differences”Insulin Glargine
Section titled “Insulin Glargine”Glargine is a recombinant human insulin analogue with two amino acid substitutions: Gly replaces Asn at position A21, and two Arg residues are added to the B-chain C-terminus (B31-Arg, B32-Arg). These modifications shift the isoelectric point from pH 5.4 (native insulin) to approximately 6.7, rendering glargine soluble at the acidic pH of the injection solution (pH 4.0) but insoluble at physiological pH 7.4.
Upon subcutaneous injection, glargine precipitates into microcrystals that slowly dissolve, releasing insulin monomers over approximately 24 hours. Glargine U-100 (Lantus) provides ~100 units/mL, while glargine U-300 (Toujeo) concentrates the same peptide into a smaller volume, creating a larger subcutaneous depot with slower dissolution kinetics.
Insulin Degludec
Section titled “Insulin Degludec”Degludec replaces ThrB30 with a non-coded amino acid and attaches a C-16 fatty hexadecanedioic acid (HDD) moiety via a γ-glutamic acid spacer to LysB29. Unlike glargine’s precipitation mechanism, degludec relies on soluble multi-hexamer chain formation. After injection, degludec monomers associate into di-hexamers via zinc-mediated coordination, which further assemble into soluble multi-hexamer chains through fatty acid-mediated interactions.
The fatty acid moiety simultaneously enables albumin binding in the subcutaneous tissue and circulation. Degludec’s half-life exceeds 42 hours, producing a flat, stable pharmacokinetic profile with day-to-day variability of less than 10% — the lowest among all basal insulins.
Comparison Table
Section titled “Comparison Table”| Property | Insulin Glargine U-100 | Insulin Glargine U-300 | Insulin Degludec |
|---|---|---|---|
| Brand names | Lantus, Basaglar | Toujeo | Tresiba |
| A21 modification | Gly (acidic pH solubility) | Gly (acidic pH solubility) | None |
| B-chain C-terminal | +2 Arg (pI shift) | +2 Arg (pI shift) | None |
| K29 fatty acid | None | None | C-16 HDD via γ-Glu spacer |
| Mechanism | pH-dependent precipitation | pH-dependent precipitation | Multi-hexamer chain + albumin binding |
| Half-life | ~12–16 hrs | ~19–26 hrs | ~42+ hrs |
| Time to peak | ~8–12 hrs | ~12–18 hrs | ~10–12 hrs (flat) |
| Duration | ~24 hrs | ~30–36 hrs | >42 hrs |
| Dosing | Once daily | Once daily | Once daily |
| Steady state | ~2–3 days | ~3–4 days | ~4–5 days |
| Day-to-day variability | ~25% | ~20% | <10% |
Pharmacokinetics and Pharmacodynamics
Section titled “Pharmacokinetics and Pharmacodynamics”Glargine U-100 achieves a relatively flat profile with a duration of approximately 24 hours, supporting once-daily dosing. However, at steady state, significant overlap occurs between consecutive doses, producing modest accumulation. The within-subject coefficient of variation (CV) for the glucose-lowering effect is approximately 25–30%.
Glargine U-300, by virtue of its three-fold higher concentration, creates a larger subcutaneous depot with slower dissolution. The half-life extends to 19–26 hours, providing a more sustained effect (30–36 hours duration) with reduced variability (CV ~20%). This pharmacokinetic advantage translates to lower nocturnal hypoglycemia risk compared to U-100.
Degludec achieves the most stable pharmacokinetic profile among all basal insulins. With a half-life exceeding 42 hours, it requires 3–4 days to reach steady state, producing a flat, constant basal insulin supply. The ultra-long half-life virtually eliminates the concept of “peaks and troughs,” and day-to-day variability in glucose-lowering effect is less than 10%.
Glycemic Outcomes
Section titled “Glycemic Outcomes”| Parameter | Glargine U-100 | Glargine U-300 | Degludec |
|---|---|---|---|
| HbA1c reduction | ~1.0–1.5% | ~1.0–1.5% | ~1.0–1.5% |
| Fasting glucose reduction | ~30–50 mg/dL | ~30–50 mg/dL | ~30–50 mg/dL |
| Target HbA1c <7% | ~40–50% | ~45–55% | ~45–55% |
| Time in range (CGM) | ~45–50% | ~50–55% | ~50–60% |
All three formulations achieve comparable HbA1c reductions. The primary differentiator is hypoglycemia risk, not efficacy. In head-to-head trials, degludec and glargine U-300 demonstrated statistically significant reductions in nocturnal hypoglycemia compared to glargine U-100, without sacrificing glycemic control.
Hypoglycemia Risk
Section titled “Hypoglycemia Risk”Nocturnal Hypoglycemia
Section titled “Nocturnal Hypoglycemia”| Trial | Comparison | Nocturnal Hypo Result |
|---|---|---|
| BEGIN | Degludec vs Glargine U-100 | 36% reduction (degludec) |
| SWITCH-1 | Degludec vs Glargine U-100 | 30% reduction (degludec) |
| CONCLUDE | Degludec vs Glargine U-300 | No significant difference |
| BRIGHT | Degludec vs Glargine U-300 | 30% reduction (degludec) |
| JBN | Glargine U-300 vs U-100 | 21% reduction (U-300) |
Degludec’s ultra-stable pharmacokinetics minimize the risk of late nocturnal hypoglycemia, particularly in the early morning hours when basal insulin requirements are lowest. The CONCLUDE trial demonstrated that degludec and glargine U-300 achieve similar nocturnal hypoglycemia rates, positioning both as superior to glargine U-100.
Overall Hypoglycemia
Section titled “Overall Hypoglycemia”- Glargine U-100: Highest overall hypoglycemia rates among the three
- Glargine U-300: Intermediate; superior to U-100 for nocturnal events
- Degludec: Lowest overall and nocturnal hypoglycemia rates
Flexibility of Dosing
Section titled “Flexibility of Dosing”Degludec uniquely supports flexible dosing (shift dosing interval by up to 8 hours between days) without increased hypoglycemia risk, enabling greater lifestyle flexibility. Glargine U-100 and U-300 require more consistent timing, as their shorter half-lives produce greater inter-dose variability when intervals are irregular.
Cardiovascular Safety
Section titled “Cardiovascular Safety”All three basal insulins have demonstrated cardiovascular safety in large outcome trials:
- ORIGIN (glargine U-100): No increase in cardiovascular events vs. standard care
- DEVOTE (degludec): Non-inferiority to glargine U-100 for MACE (HR 0.91, p=0.002 for non-inferiority)
- CONCLUDE extension (glargine U-300): Consistent with CV safety
Degludec’s DEVOTE trial also demonstrated a 40% reduction in severe hypoglycemia (HR 0.60, p<0.001), a finding not replicated with glargine U-300 in the BRIGHT trial.
Clinical Decision Framework
Section titled “Clinical Decision Framework”Choose glargine U-100 when:
- Cost is the primary concern (most affordable long-acting insulin)
- Patient achieves stable glycemic control on U-100
- Simplicity of established regimen is preferred
- Basal insulin requirements <60 units/day
Choose glargine U-300 when:
- Reduced nocturnal hypoglycemia is desired over U-100
- Patient injects high volumes and wants smaller injection volumes (Toujeo Solostar has 0.5 mL pen)
- Cost-conscious but willing to pay premium for improved safety profile
- Flexibility in dosing is not critical
Choose degludec when:
- Lowest hypoglycemia risk is paramount (especially severe/nocturnal)
- Flexible dosing is required (shift workers, variable schedules)
- History of hypoglycemia unawareness
- Cardiovascular disease with hypoglycemia risk concerns
- Patient preference for ultra-long duration of action
References
Section titled “References”- Owens DR, et al. “Insulin glargine: pharmacokinetics and comparison with other long-acting insulin analogues.” Diabetes Obes Metab 2002;4:223-229.
- Heise T, et al. “Insulin degludec: pharmacokinetics, pharmacodynamics, and safety in type 2 diabetes.” Diabetes Obes Metab 2014;16:1149-1153.
- Marso SP, et al. “Insulin degludec and cardiovascular outcomes in patients with type 2 diabetes (DEVOTE).” NEJM 2017;377:723-732.
- Matsuhisa M, et al. “Insulin glargine U-300 vs U-100 in type 2 diabetes (JBN).” Diabetes Obes Metab 2018;20:1528-1534.
- Rosenstock J, et al. “Degludec vs glargine U-300 in basal insulin-treated type 2 diabetes (CONCLUDE).” Lancet Diabetes Endocrinol 2019;7:188-199.